Terminated PHASE1/PHASE2 INTERVENTIONAL 14-arm NCT02711137

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Sponsor: Incyte Corporation

Conditions Solid Tumors

Interventions Abiraterone Azacitidine Gemcitabine INCB057643 Paclitaxel Rucaparib Ruxolitinib

Updated 18 times since 2017 Last updated: Oct 20, 2025 Started: May 18, 2016 Primary completion: Feb 13, 2019 Completion: Feb 13, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Study terminated due to safety issues.

Other terminated trials from Incyte Corporation

More terminations from Incyte Corporation

Other Solid Tumors trials with similar outcome

Browse all Solid Tumors trials

A PHASE1/PHASE2 clinical study on Solid Tumors, this trial is terminated or withdrawn. The trial is conducted by Incyte Corporation and has accumulated 18 data snapshots since 2016. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

18 versions recorded

Nov 2025 — Present [monthly]

Terminated PHASE1/PHASE2
Sep 2025 — Nov 2025 [monthly]

Terminated PHASE1/PHASE2
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
May 2022 — Jul 2024 [monthly]

Terminated PHASE1_PHASE2

▶ Show 13 earlier versions

Apr 2022 — May 2022 [monthly]

Terminated PHASE1_PHASE2
Jan 2021 — Apr 2022 [monthly]

Terminated PHASE1_PHASE2
Mar 2020 — Jan 2021 [monthly]

Terminated PHASE1_PHASE2
Jan 2020 — Mar 2020 [monthly]

Terminated PHASE1_PHASE2
Dec 2019 — Jan 2020 [monthly]

Terminated PHASE1_PHASE2
Jun 2019 — Dec 2019 [monthly]

Terminated PHASE1_PHASE2

Status: Active Not Recruiting → Terminated
Oct 2018 — Jun 2019 [monthly]

Active Not Recruiting PHASE1_PHASE2
Jun 2018 — Oct 2018 [monthly]

Active Not Recruiting PHASE1_PHASE2

Status: Recruiting → Active Not Recruiting
Apr 2018 — Jun 2018 [monthly]

Recruiting PHASE1_PHASE2
Dec 2017 — Apr 2018 [monthly]

Recruiting PHASE1_PHASE2
Jun 2017 — Dec 2017 [monthly]

Recruiting PHASE1_PHASE2
Feb 2017 — Jun 2017 [monthly]

Recruiting PHASE1_PHASE2
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE1_PHASE2

First recorded

May 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Incyte Corporation

Data source: Incyte Corporation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States , Birmingham, United States , Brussels, Belgium , Chapel Hill, United States , Denver, United States , Houston, United States , La Jolla, United States , Miami, United States , Minneapolis, United States , New Haven, United States and 7 more locations